Showing 3731-3740 of 8660 results for "".
- FDA Accepts Arcutis Biotherapeutics’ NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-arcutis-biotherapeutics-nda-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/2461018/The FDA accepted Arcutis Biotherapeutics’ new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022. “With the FDA c
- Cytrellis Secures New Round of Fundinghttps://practicaldermatology.com/news/cytrellis-secures-new-round-of-funding/2460920/Cytrellis has closed a $50 million Series C funding round. The financing was led by D1 Capital Partners and included participation from an additional new investor, Sands Capital, as well as existing institutional investors, ARCH Venture Partners and PFM Health Sciences. Proceeds will be
- Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officerhttps://practicaldermatology.com/news/industry-veteran-ann-deren-lewis-joins-mindera-as-chief-commercial-officer/2460879/Ann Deren-Lewis is Mindera’s new Chief Commercial Officer. She most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical c
- Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Wartshttps://practicaldermatology.com/news/verrica-pharmaceuticals-positive-data-for-vp-102-for-molluscum-contagiosum-warts/2460187/Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product candidate is being developed for the treatment of molluscum c
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c
- New AAD Acne Guidelines Call for Combination Therapyhttps://practicaldermatology.com/news/new-aad-acne-guidelines-call-for-combination-therapy/2458695/Combination therapy is the way forward for treating moderate-to-mild acne, according to new guidelines from The American Academy of Dermatology. For example, antibiotics should be used with topical acne therapy, and patients should continue using topical treatments to manage their c
- Pfizer Outlines Post-Allergan Deal Leadership Team Changeshttps://practicaldermatology.com/news/pfizer-outlines-post-allergan-deal-leadership-team-changes/2458709/Brent Saunders will become President and Chief Operating Officer of the combined Pfizer and Allergan company following the close of the merger deal. In this role, he will over see Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions. The c
- Dr. Andrew Krakowski Now CMO at DermOnehttps://practicaldermatology.com/news/andrew-krakowski-now-cmo-at-dermone/2458729/Andrew C. Krakowski, MD has joined DermOne, a network of comprehensive dermatology practices, as Chief Medical Officer. “The need for dermatology services has accelerated in recent years, due to an aging population, a growing demand for surgical and cosmetic procedures and a raised
- Surgical Specialties Corporation Acquires FSSB Chirurgische Nadein GMBHhttps://practicaldermatology.com/news/surgical-specialties-corporation-acquires-fssb-chirurgische-nadein-gmbh/2458735/Surgical Specialties Corporation has acquired all shares of FSSB Chirurgische Nadein GMBH (FSSB) and affiliated entities. Terms were not disclosed. The acquisition will be immediately accretive to both Surgical Specialties' sales and adjusted EBITDA. FSSB was founded in 1995 by c
- Court Rules in Favor of Amarin Corp. in "Off-label" Disputehttps://practicaldermatology.com/news/court-rules-in-favor-of-amarin-corp-in-off-label-dispute/2458897/Amarin Corporation plc (NASDAQ: AMRN) today announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin'slead product, Vascepa®(icosapent ethyl) c